Approximately 3%–5% of patients with NSCLC belonged to anaplastic lymphoma kinase (ALK)-positive NSCLC which provided opportunities for targeted therapy (Chen et al., 2021). The gene discussed is ALK; the disease is non-small cell lung carcinoma.